TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04563507

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions)
Description: Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT. They will undergo tumor Immunogenic-SBRT(I-SBRT) days 1-12 (+/-2 days, to enable inclusion of holidays). During the week preceding day 1, they will undergo simulation and planning for radiotherapy. Each oligometastatic lesion will be treated with I-SBRT every 48 hours. Treatment may be given daily (to keep the total I-SBRT treatment time to ≤ 12 days) and lesions targeted with I-SBRT will thus be alternated each day to accommodate for the 48 hour interval between fractions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole 2.5Mg Tab
Description: All patients start standard therapy with oral letrozole (Femara), day 1 of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole 2.5Mg Tab
Description: All patients start standard therapy with oral letrozole (Femara), day 1 of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib 125mg
Description: Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib 125mg
Description: Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT.
Study: NCT04452721

Intervention type: OTHER
Intervention: dynamic compression system
Description: It is a harness that the patient wears all day long for an average duration of 1 year, and that remodels the chest by exerting a moderate pressure on it

Intervention type: OTHER
Intervention: dynamic compression system
Description: It is a harness that the patient wears all day long for an average duration of 1 year, and that remodels the chest by exerting a moderate pressure on it
Study: NCT02737436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin
Description: Intranasal oxytocin (24IU) given 50 minutes prior to behavior assessment or scanning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intranasal placebo spray given 50 minutes prior to behavior assessment or scanning

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional MRI scanning
Description: All study participants underwent two functional MRI scanning visits. On one occasion this was after receiving an intranasal dose of oxytocin; on the other occasions, after receiving intranasal placebo dose.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional MRI scanning
Description: All study participants underwent two functional MRI scanning visits. On one occasion this was after receiving an intranasal dose of oxytocin; on the other occasions, after receiving intranasal placebo dose.
Study: NCT03697070

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: INSPIRE CPOE Smart Prompt
Description: Quality improvement intervention: computerized physician order entry (CPOE) decision support alert that provides physicians with patient-specific risk estimate of having PNA due to a multidrug resistant organism (MDRO) and recommends appropriate antibiotic choice for non-ICU patients in the first 3 days of hospitalization.~Continuation of other antibiotic stewardship activities in accordance with national standards.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care
Description: Routine Antibiotic Stewardship Arm - Continuation of all antibiotic stewardship activities in accordance with national standards.
Study: NCT04544436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: The actual higher dose of ocrelizumab will be assigned to participants based on their body weight at baseline: 1200 mg (body weight \<75 kg) or 1800 mg (body weight ≥ 75 kg). The first dose of ocrelizumab will be administered as two 600 mg or 900 mg IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 1200 mg or 1800 mg IV infusion Q24W. During the optional OLE phase, participants will continue with their assigned dose of ocrelizumab (either 1200 or 1800 mg) for approximately 96 weeks (4 doses in total).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ocrelizumab
Description: Ocrelizumab will be administered at a dose of 600 mg Q24W. The first dose of ocrelizumab will be administered as two 300 mg IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 600 mg IV infusion Q24W.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antihistamine
Description: Premedication with oral or IV antihistaminic drug (i.e., diphenhydramine 50 mg or an equivalent dose of an alternative) will be administered prior to each ocrelizumab infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihistamine
Description: Premedication with oral or IV antihistaminic drug (i.e., diphenhydramine 50 mg or an equivalent dose of an alternative) will be administered prior to each ocrelizumab infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Premedication with 100 mg of methylprednisolone (or equivalent) will be administered by IV infusion prior to each ocrelizumab infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Premedication with 100 mg of methylprednisolone (or equivalent) will be administered by IV infusion prior to each ocrelizumab infusion.
Study: NCT02672917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVT-5873
Description: intravenous infusion (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVT-5873
Description: intravenous infusion (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVT-5873
Description: intravenous infusion (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVT-5873
Description: intravenous infusion (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVT-5873
Description: intravenous infusion (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVT-5873
Description: intravenous infusion (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modified FOLFIRINOX (mFOLFIRINOX)
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modified FOLFIRINOX (mFOLFIRINOX)
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine + nab-paclitaxel
Description: IV
Study: NCT04565210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music exposure
Description: Participants will be offered individual sessions of music. They will be exposed for 10 minutes per day, 3 days per week for a period of 2 weeks using a headphone.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music exposure
Description: Participants will be offered individual sessions of music. They will be exposed for 10 minutes per day, 3 days per week for a period of 2 weeks using a headphone.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Silence
Description: Participants in this group will be offered individual silence session for 10 minutes per day, 3 days per week for a period of 2 weeks using a headphone.
Study: NCT02587897

Intervention type: OTHER
Intervention: Academic Coursework
Description: Didactic training provided by the university through coursework and laboratory training that meets requirements of the accreditation standards provided by the professional society associated with each professional degree granting program.

Intervention type: OTHER
Intervention: Academic Coursework
Description: Didactic training provided by the university through coursework and laboratory training that meets requirements of the accreditation standards provided by the professional society associated with each professional degree granting program.

Intervention type: OTHER
Intervention: Work-Related Hand Activities
Description: Exposure to intensive training in the use of dental scaling tools as part of laboratory courses, as well as fieldwork and residency training during the academic degree program.
Study: NCT03075254

Intervention type: DEVICE
Intervention: A Peltier for Sensory testing
Description: Subjects will be trained to rate the magnitude of late sensations elicited following brief (700 msec) contact of a preheated thermode with the glabrous (palmar) skin of either hand/foot either numerically or using a visual analogue scale.

Intervention type: DEVICE
Intervention: A Peltier for Sensory testing
Description: Subjects will be trained to rate the magnitude of late sensations elicited following brief (700 msec) contact of a preheated thermode with the glabrous (palmar) skin of either hand/foot either numerically or using a visual analogue scale.

Intervention type: DEVICE
Intervention: A Peltier for Sensory testing
Description: Subjects will be trained to rate the magnitude of late sensations elicited following brief (700 msec) contact of a preheated thermode with the glabrous (palmar) skin of either hand/foot either numerically or using a visual analogue scale.

Intervention type: DEVICE
Intervention: functional magnetic resonance imaging for Brain Neuroimaging
Description: to evaluate baseline changes in regional cerebral blood flow to nociceptive thermal stimuli applied to the extremities of FM patients and healthy volunteers.

Intervention type: DEVICE
Intervention: functional magnetic resonance imaging for Brain Neuroimaging
Description: to evaluate baseline changes in regional cerebral blood flow to nociceptive thermal stimuli applied to the extremities of FM patients and healthy volunteers.

Intervention type: DEVICE
Intervention: functional magnetic resonance imaging for Brain Neuroimaging
Description: to evaluate baseline changes in regional cerebral blood flow to nociceptive thermal stimuli applied to the extremities of FM patients and healthy volunteers.
Study: NCT02727803

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Natural Killer Cell Line NK-92
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Natural Killer Cell Line NK-92
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Natural Killer Cell Line NK-92
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo total body irradiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo total body irradiation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation
Description: Undergo umbilical cord blood transplantation
Study: NCT02774785

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MarginProbe
Description: Surgery to take place as per standard care. When the surgery is nearly concluded, patient to be randomised. If randomised to device arm, the MarginProbe device will be used on the outer edge of the tumour and shavings. If the MarginProbe device indicates that cancer is detected, a further shaving is to be taken. Surgery then to be concluded as per standard care.
Study: NCT02727803

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation
Description: Undergo umbilical cord blood transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation
Description: Undergo umbilical cord blood transplantation
Study: NCT03274687

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation therapy
Description: 66.6 Gy in 37 daily fractions of 1.8 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional radiation therapy
Description: 62.5 Gy in 25 daily fractions of 2.5 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optional androgen deprivation therapy
Description: Any luteinizing hormone-releasing hormone (LHRH) agonist/antagonist with or without an oral antiandrogen can be used up to a six-month administration dose, starting 7-9 weeks before radiation therapy and may begin as early as 42 days prior to or any time after screening. An oral antiandrogen alone is not allowed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optional androgen deprivation therapy
Description: Any luteinizing hormone-releasing hormone (LHRH) agonist/antagonist with or without an oral antiandrogen can be used up to a six-month administration dose, starting 7-9 weeks before radiation therapy and may begin as early as 42 days prior to or any time after screening. An oral antiandrogen alone is not allowed.
Study: NCT03079024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Targeted Cognitive Training
Description: 1. Auditory Training Module (20 hours): exercises designed to improve speed and accuracy of auditory processing while engaging working memory and cognitive control. Exercises adjust difficulty level to maintain an \~80% correct performance. Exercises contain stimuli spanning the acoustic organization of speech. In the initial stages, stimuli exaggerate the rapid temporal transitions by increasing amplitude and stretching in time. The exaggeration is gradually removed so that by the end, all stimuli have characteristics representative of real-world speech.~2. Social Cognition Module (10 hours): exercises designed to improve core deficits of social cognition in psychosis. Exercises apply principles of implicit learning to restore capacity to process and utilize socially-relevant information, and includes training to improve perception of affect (visual/vocal) and social cues (faces, gazes, social situations), theory of mind, self-referential style, emotion labeling and working memory.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: General Cognitive Exercises
Description: The GCE will focus on executive dysfunction, as this domain is a significant, functionally important area of deficit in schizophrenia and has been the target of many previous studies. We will train this domain using a suite of engaging, adaptive web-based exercises that target executive function, intelligence, and spatial navigation developed by Posit Science. The exercises will be provide engaging, adaptive training as described in the Targeted Cognitive Training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinated Specialty Care for First Episode Psychosis
Description: Individuals in this study are receiving care from a coordinated specialty care clinic (CSC) for first episode psychosis. These clinics are following the NAVIGATE treatment model for early psychosis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinated Specialty Care for First Episode Psychosis
Description: Individuals in this study are receiving care from a coordinated specialty care clinic (CSC) for first episode psychosis. These clinics are following the NAVIGATE treatment model for early psychosis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coordinated Specialty Care for First Episode Psychosis
Description: Individuals in this study are receiving care from a coordinated specialty care clinic (CSC) for first episode psychosis. These clinics are following the NAVIGATE treatment model for early psychosis.
Study: NCT00601627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT04115930

Intervention type: DEVICE
Intervention: Physical Activity measurement:
Description: 7 days measurement with Active style Pro HJA-350IT device

Intervention type: DEVICE
Intervention: Physical Activity measurement:
Description: 7 days measurement with Active style Pro HJA-350IT device
Study: NCT01071226

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS (CD+3, CD+19 depletion)
Description: Patient's in Stratum 1 will receive grafts that have undergone CD3+, CD19+ depletion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS (CD 34+ positive selection)
Description: Patient's in Stratum 2 will receive peripheral blood progenitor cells that have undergone CD34+ selection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HSCT
Description: Peripheral Blood Stem Cell Transplant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HSCT
Description: Peripheral Blood Stem Cell Transplant
Study: NCT04360135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Preemptive acetaminophen the day before surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Preemptive placebo the day before surgery
Study: NCT04080284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Study treatment will be administered orally Q day continuously. Up to three capsules of 100mg strength will be taken at each dose administration. Initiation dose will be defined per current FDA guidelines for Niraparib treatment in ovarian cancer. Dose interruption (no longer than 28 days) will be allowed. Dose reduction will be allowed based on treatment side effects. Dose reductions to 2 capsules daily (200mg) and subsequently to 1 capsule daily (100mg) will be allowed. No further dose reductions will be allowed. The timing of efficacy or safety evaluations should not be affected by dose interruptions or reductions.
Study: NCT04605770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed+cisplatin
Description: Pemetrexed 500 mg/m2 (Day 1) and cisplatin 75 mg/m2 (Day 1) will be given via intravenous (IV) infusion. Each cycle consists of 21 days, and this combination therapy will be continued until Cycle 6. Starting from Cycle 7, pemetrexed alone will be administered every 3 weeks (Q3W) as IV infusion until disease progression.~Vitamin B12 1000 mcg intramuscular (IM) injection will be given within 14 days prior to the first dose of pemetrexed, every 9 weeks (on the same day as study treatment) thereafter, and then 21 days after the last dose of pemetrexed. Folic acid 1 mg will be administered daily starting from 14 days before the first dose of pemetrexed and continued until 21 days after the last dose of pemetrexed. Study treatment will be continued until PD, unacceptable AE, or decision to discontinue by subject or physician.
Study: NCT01848834

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT01237691

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOPE supervision
Description: HOPE entails a warning session (Orientation Hearing) where the rules of parole are laid out and parolees are told that any violation of stated parole conditions will be sanctioned with a brief jail term (typically a few days in jail). HOPE includes regular random drug testing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parole-as-usual
Description: Parolees are supervised under standard parole supervision practice in California.
Study: NCT02324660

Intervention type: OTHER
Group type: OTHER
Intervention: screening test
Description: screening test with peak expiratory flow and respiratory health screening questionnaire to discriminate patients at risk for COPD
Study: NCT02056691

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise programme
Description: The exercise regime consists of 10 sessions of exercise against a constant load, each lasting 60 seconds, separated by 60 seconds of recovery eliciting 90% maximal heart rate. The 6 sessions are held over a 2 week period.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle biopsy
Description: muscle biopsy under local anaesthetic taken from the thigh, again for analysis and storage 3 times: before, during and after the exercise programme